Recent Updates
Recently added Catalysts
KRMD Positive Sentiment

KORU Medical Systems Announces Second Quarter 2026 Results and Updates Full Year 2026 Guidance

Key Takeaway: KORU Medical Systems reported an 18% increase in net revenues for the second quarter of 2026. The company also provided an updated guidance for the full year, indicating a positive outlook for its financial performance. This growth reflects KORU's commitment to developing innovative subcutaneous infusion solutions.
Price reaction · baseline $4.13 (2026-08-05 close) · hit after-hours · clean, no other KRMD news in the window
day 0 close
-13.8%
day 1
-14%
day 3 · peak
-16.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Net revenues grew 18% over the previous quarter.
  • The company is focused on innovative and patient-centric solutions.
  • Updated guidance for full year 2026 indicates growth potential.

Full Press Release Details

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the second quarter ended June 30, 2026. The Company also updated guidance for the full year 2026. Second Quarter 2026 and Recent Highlights Net revenues grew 18% over the p

Frequently Asked Questions

What were KORU Medical's Q2 2026 net revenues?

KORU Medical reported an 18% increase in net revenues for Q2 2026.

What does KORU Medical focus on?

KORU Medical specializes in patient-centric large volume subcutaneous infusion solutions.

Did KORU Medical update its 2026 guidance?

Yes, KORU Medical updated its guidance for the full year 2026.

Last updated: Aug 5, 2026